NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 155 filers reported holding NEKTAR THERAPEUTICS in Q1 2015. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $394,000 | -55.0% | 8,068 | -2.0% | 0.28% | -58.2% |
| Q1 2018 | $875,000 | -16.5% | 8,230 | -53.1% | 0.67% | -17.7% |
| Q4 2017 | $1,048,000 | +5.6% | 17,542 | -57.5% | 0.82% | -6.8% |
| Q3 2017 | $992,000 | +22.5% | 41,316 | -0.3% | 0.88% | +22.8% |
| Q2 2017 | $810,000 | -18.0% | 41,420 | -1.6% | 0.71% | -7.0% |
| Q1 2017 | $988,000 | +91.1% | 42,109 | -0.0% | 0.77% | +92.5% |
| Q4 2016 | $517,000 | -31.3% | 42,124 | -3.9% | 0.40% | -35.2% |
| Q3 2016 | $753,000 | +13.6% | 43,851 | -6.0% | 0.62% | +3.5% |
| Q2 2016 | $663,000 | -70.9% | 46,626 | -71.8% | 0.60% | -69.1% |
| Q1 2016 | $2,277,000 | -25.2% | 165,584 | -8.3% | 1.92% | -13.0% |
| Q4 2015 | $3,043,000 | +47.5% | 180,601 | -4.0% | 2.21% | +50.6% |
| Q3 2015 | $2,063,000 | +184.2% | 188,220 | +224.2% | 1.47% | +220.0% |
| Q2 2015 | $726,000 | +53.8% | 58,053 | +35.2% | 0.46% | +67.5% |
| Q1 2015 | $472,000 | – | 42,938 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |